Navigation Links
Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012
Date:5/7/2012

MARLBOROUGH, Mass., May 7, 2012 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System (EAS) for the treatment of atrial fibrillation (AF), announces that its technology will be highlighted both as part of the scientific sessions and during a private academic symposium at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions, May 9-12 in Boston, MA. The presentations will feature clinical experiences and outcomes using the company's technology, the first visually-guided laser balloon ablation system.

"We are pleased that over two years of comprehensive clinical experiences with our technology will be featured at this prominent industry conference. Many of the leading international experts in heart rhythm management will be participating in these sessions and presenting their own findings with the HeartLight EAS, and we anticipate engaging discussion on the applicability of the system in clinical practice," said Stephen Sagon, President and CEO of CardioFocus.

During the scientific sessions, the presentation "Worldwide Experience Using the Endoscopic Ablation System for Ablation of Atrial Fibrillation" will give an overview of the feasibility and safety of AF ablation using the HeartLight EAS, with findings representing the first patients treated with the technology by 32 different operators across 19 medical centers. The presentation will be made by Boris Schmidt, MD, of Cardioangiologisches Centrum Bethanien, Frankfurt, Germany on Friday, May 11 at 3:25 p.m. ET.

The HeartLight EAS Symposium, to be held the evening of Thursday, May 10 at the Renaissance Boston Waterfront Hotel, will feature presentations from cardiology thought leaders on the evolution of pulmonary vein (PV) isolation ablation, the adoption of the new visually-guided laser balloon ablation technique, and the clinical experiences with the technology at centers throughout Europe. It will be chaired by Prof. Petr Neuzil, MD, of Na Homolce Hospital, Prague, Czech Republic and Prof. Thorsten Lewalter, MD, of Isar Heart Center, Munich, Germany.

The HeartLight EAS is a unique catheter ablation technology that incorporates an endoscope for direct visualization of the inside of the heart and a compliant, dynamically adjustable balloon catheter designed for improved contact with the PV ostium irrespective of the individual patient anatomy. It also utilizes laser energy for more efficient, durable and precise ablation treatment. 

The system is available in Europe for the treatment of AF, and is currently the focus of a pivotal trial in the U.S. For more information, please visit the CardioFocus booth #1103 or www.CardioFocus.com.

About CardioFocus, Inc.CardioFocus, Inc. is a medical device manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF). Its novel HeartLight® Endoscopic Ablation System for catheter ablation incorporates an endoscope to provide physicians with the capacity to see within the heart, and for the first time, visually direct the application of laser energy to achieve durable pulmonary vein isolation.

The HeartLight Endoscopic Ablation System is commercially available at leading institutions throughout Europe. The device is investigational in the U.S., and currently the focus of a pivotal trial initiated in 2012. CardioFocus is headquartered in Marlborough, MA, USA.  For more information on the company and its technology, please visit www.CardioFocus.com.

The scientific information discussed in this news release is preliminary and investigative. The CardioFocus HeartLight Endoscopic Ablation System is not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the system. Only FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Healthcare professionals should refer to/rely upon FDA-approved labeling for the products, and not the information discussed in this news release.Company Contact:

Media Contact:Anjie Roldan

Lisa CookVice President Finance

(646) 536-7012(508) 658-7237

lcook@theruthgroup.com aroldan@cardiofocus.com
'/>"/>

SOURCE CardioFocus, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Telemedicine Monitoring: Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018
2. ResearchMoz: Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018 - Market Research Report
3. Leading Pharma Events CPhI Worldwide, ICSE, P-MEC Europe & InnoPack to Return to Frankfurt in 2013 after Record Breaking Year
4. Prometheus Signs Research & Collaboration Agreement with Leading Worldwide Pharmaceutical Company
5. Cardica Achieves Key Milestone With Over 25,000 PAS-Port® Proximal Anastomosis Systems Deployed Worldwide
6. UH Case Medical Center the First in Region to Enroll Patients in Worldwide Study
7. Thermogenesis Signs Worldwide Res-Q System Distribution Agreement With Arthrex for Sports Medicine Applications
8. The Outlook for Medical Devices Worldwide
9. The Outlook for Pharmaceuticals Worldwide
10. BioDelivery Sciences Announces Worldwide License and Development Agreement with Endo Pharmaceuticals for BEMA Buprenorphine
11. Medical Centers Worldwide Adopt Both Accurays CyberKnife and TomoTherapy Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
Breaking Medicine News(10 mins):